Castle Biosciences raised its revenue guidance for 2026 to between $365 million and $375 million [1].
The update follows a strong second quarter that signals expanding market adoption of the company's diagnostic tools. This growth is primarily attributed to the performance of TissueCypher, which has seen significant volume trends.
During an earnings call on July 30, the company reported revenue of $103.5 million for the second quarter of 2026 [1, 2]. This figure represents a 20% increase compared to the second quarter of 2025 [1]. Derek Maetzold, the company's CEO, said the performance was a "great quarter" [1].
The company's operational growth extended to its testing volume. Total test reports for the second quarter of 2026 increased by 32% over the same period in 2025 [2]. This surge in testing suggests a broader clinical uptake of the company's molecular diagnostics.
Maetzold said, "We delivered revenue of $103.5 million, 20% growth compared to the second quarter of 2025."
The upward revision of the 2026 guidance reflects the company's confidence in its current trajectory. Maetzold said, "We believe we will continue this positive momentum in the second half of 2026," [1].
The company's financial outlook is now anchored by the sustained volume growth of TissueCypher, a key driver in their current portfolio, and the overall increase in diagnostic reportings [1, 2].
““What a great quarter.””
The upward revision of revenue guidance indicates that Castle Biosciences is successfully scaling its TissueCypher product. By increasing both total test reports and overall revenue, the company is demonstrating a transition from initial product launch to sustained market penetration in the molecular diagnostics space.
